share_log

Investors Ignore Increasing Losses at Xiangxue PharmaceuticalLtd (SZSE:300147) as Stock Jumps 5.0% This Past Week

Investors Ignore Increasing Losses at Xiangxue PharmaceuticalLtd (SZSE:300147) as Stock Jumps 5.0% This Past Week

投資者忽視了翔雪藥業有限公司(SZSE:300147)日益增加的虧損,股價在過去一週上漲了5.0%。
Simply Wall St ·  2024/12/11 17:52

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! For example, the Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) share price has soared 121% return in just a single year. Also pleasing for shareholders was the 92% gain in the last three months. And shareholders have also done well over the long term, with an increase of 95% in the last three years.

購買公司的股份時,總是存在價格跌至零的風險。另一方面,如果你找到一家高質量的業務進行購買(以合適的價格),你可以實現資金翻倍!例如,香雪製藥股份有限公司(SZSE:300147)的股價在僅僅一年內上漲了121%。對於股東來說,過去三個月也令人滿意,漲幅達到92%。而且,在長期期間,股東們的表現也很好,過去三年增長了95%。

The past week has proven to be lucrative for Xiangxue PharmaceuticalLtd investors, so let's see if fundamentals drove the company's one-year performance.

過去一週對香雪製藥的投資者來說是豐厚的收益,讓我們看看基本面是否推動了公司的年度業績。

Given that Xiangxue PharmaceuticalLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

鑑於香雪製藥在過去十二個月沒有盈利,我們將重點關注營業收入的增長,以快速了解其業務發展。無盈利公司的股東通常希望看到強勁的營業收入增長。如你所想,快速的營業收入增長在保持的情況下,往往會導致快速的利潤增長。

In the last year Xiangxue PharmaceuticalLtd saw its revenue shrink by 3.0%. So we would not have expected the share price to rise 121%. This is a good example of how buyers can push up prices even before the fundamental metrics show much growth. It's quite likely the revenue fall was already priced in, anyway.

在過去一年,香雪製藥的營業收入下降了3.0%。因此我們本不會預期股價上漲121%。這是一個很好的例子,說明即使基本指標尚未顯示出顯著增長,買家仍然可以推高價格。無論如何,營收下滑很可能已經被市場消化。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下面的圖像中查看收益和營業收入隨時間的變化(點擊圖表查看確切值)。

big
SZSE:300147 Earnings and Revenue Growth December 12th 2024
SZSE:300147盈利和營業收入增長 2024年12月12日

This free interactive report on Xiangxue PharmaceuticalLtd's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步研究香雪製藥的股票,這份關於香雪製藥有限公司資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

It's good to see that Xiangxue PharmaceuticalLtd has rewarded shareholders with a total shareholder return of 121% in the last twelve months. That's better than the annualised return of 9% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Xiangxue PharmaceuticalLtd better, we need to consider many other factors. To that end, you should be aware of the 3 warning signs we've spotted with Xiangxue PharmaceuticalLtd .

很高興看到香雪製藥有限公司在過去十二個月中給股東帶來了121%的總股東回報。這比過去五年年均9%的回報好,意味着公司最近的表現更佳。鑑於股價動能依然強勁,可能值得仔細觀察這隻股票,以免錯失機會。長期跟蹤股價表現總是很有趣。但爲了更好地理解香雪製藥有限公司,我們需要考慮很多其他因素。爲此,你應該注意到我們發現的香雪製藥有限公司的3個警告信號。

But note: Xiangxue PharmaceuticalLtd may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

但請注意:香雪製藥有限公司可能不是最佳的買入股票。因此請查看此份關於過去盈利增長(以及進一步增長預測)的有趣公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文中引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論